Clarithromycin

Contraindicated

Clarithromycin Colchicine Colcrys Explained Increased colchicine exposure and an increased risk of colchicine toxicity Details Clarithromycin Simvastatin Flolipid Explained An increased risk of myopathy or rhabdomyolysis Details Clarithromycin Alfuzosin UroXatral Increased alfuzosin exposure and an increased risk of QT interval prolongation Details Clarithromycin Dihydroergotamine Injection DHE-45® Injection Increased dihydroergotamine exposure and an increased risk of acute ergot toxicity (ergotism) Details Clarithromycin Dihydroergotamine Nasal Spray Migranal Increased dihydroergotamine exposure and an increased risk of acute ergot toxicity (ergotism) Details Clarithromycin Finerenone Kerendia Increased finerenone exposure and an increased risk of finerenone-related adverse effects Details Clarithromycin Ivabradine Corlanor Increased ivabradine exposure, an increased risk of ivabradine-related adverse effects and an increased risk of QT prolongation Details Clarithromycin Ketoconazole Topical Extina® Foam Increased clarithromycin exposure, an increased ketoconazole exposure and an increased risk of QT interval prolongation Details Clarithromycin Lovastatin Altocor® An increased lovastatin exposure and an increased risk of myopathy or rhabdomyolysis Details Clarithromycin Lurasidone Latuda Increased lurasidone exposure Details Clarithromycin Naloxegol Movantik Increased naloxegol exposure and an increased risk of naloxegol-related adverse effects Details Clarithromycin Nimodipine Nimotop Increased nimodipine exposure and risk of significant hypotension Details

Major

Clarithromycin Acetaminophen And Codeine Capital® & Codeine Explained Increased codeine and morphine exposure Details Clarithromycin Abametapir Explained Increased exposure of CYP3A4 substrate Details Clarithromycin Clindamycin ANTIROBE Explained Increased exposure of CYP3A4 substrate and risk for toxicity Details Clarithromycin Omeprazole Gastrobim Explained Increased clarithromycin exposure in gastric tissue and mucus and an increased omeprazole exposure Details Clarithromycin Amitriptyline Elavil Explained Increased risk of QT interval prolongation Details Clarithromycin Sertraline Explained Increased risk of QT interval prolongation, increased exposure of CYP3A4 substrate and risk for toxicity Details Clarithromycin Buprenorphine Belbuca Explained An increased risk of QT interval prolongation, increased buprenorphine exposure and an increased risk of buprenorphine-related adv... Details Clarithromycin Relugolix Orgovyx Explained Increased relugolix exposure and an increased risk of QT interval prolongation Details Clarithromycin Acalabrutinib Calquence Increased acalabrutinib exposure Details Clarithromycin Ado-Trastuzumab Emtansine Injection KADCYLA Increased exposure of cytotoxic component DM1 (maytansine derivative) and risk of toxicity Details Clarithromycin Amisulpride Injection Barhemsys Increased risk of serious ventricular arrhythmias such as torsades de pointes Details Clarithromycin Arsenic Trioxide Trisenox An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Clarithromycin Aripiprazole Injection Abilify Increased ARIPiprazole exposure and an increased risk of QT interval prolongation Details Clarithromycin Arsenic Trioxide Injection Trisenox An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Clarithromycin Asciminib Scemblix Increased asciminib exposure and an increased risk of asciminib-related adverse effects Details Clarithromycin Asenapine Transdermal Patch Secuado Increased risk of QT interval prolongation and torsade de pointes Details Clarithromycin Atogepant Qulipta Increased atogepant exposure Details Clarithromycin Avapritinib Ayvakit Increased avapritinib exposure and increased incidence and severity of adverse reactions Details Clarithromycin Avatrombopag Doptelet Increased exposure of CYP3A4 substrate and risk for toxicity Details Clarithromycin Azathioprine Azasan An increased risk of hepatotoxicity Details Clarithromycin Azithromycin AzaSite An increased risk of QT interval prolongation Details Clarithromycin Belumosudil Rezurock Explained Increased exposure of CYP3A4 substrate and risk for toxicity Details Clarithromycin Betrixaban Bevyxxa® Increased betrixaban exposure and increased risk of bleeding Details Clarithromycin Atorvastatin Atorvaliq Increased atorvastatin exposure and an increased risk of myopathy or rhabdomyolysis Details Clarithromycin Cariprazine Vraylar Explained Increased exposure to cariprazine and its active metabolite, didesmethylcariprazine Details Clarithromycin Abiraterone Abirtega Increased exposure of CYP3A4 substrate and risk for toxicity Details Clarithromycin Afatinib Gilotrif Increased exposure of afatinib Details Clarithromycin Amlodipine Amvaz® Increased risk of hypotension, acute kidney injury, bradyarrhythmias, lactic acidosis and peripheral edema Details